The National Vaccine Information Center (NVIC) today released a new analysis of the federal Vaccine Adverse Event Reporting System (VAERS) reports of serious health problems following HPV vaccination (Merck's GARDASIL) during the last six months of 2006. Out of the 385 individual GARDASIL adverse event reports made to VAERS, two-thirds required additional medical care and about one-third of all reports were for children 16-years-old and under, with nearly 25 percent of those children having received simultaneously one or more of the 18 vaccines that Merck did not study in combination with GARDASIL. NVIC is calling on the FDA and CDC to warn parents and doctors that GARDASIL should not be combined with other vaccines and that young girls should be monitored for at least 24 hours for syncopal (collapse/fainting) episodes that can be accompanied by seizure activity, as well as symptoms of tingling, numbness and loss of sensation in the fingers and limbs, all of which should be reported to VAERS immediately.

"If only 1 to 4 percent of all adverse events associated with GARDASIL vaccination are being reported to VAERS, there could have been up to 38,000 health problems after GARDASIL vaccination in 2006 which were never reported," said Fisher. "How many girls are really having short-term health problems associated with getting this vaccine that could turn into long-term neurological or immune system disorders? And how many will go on to develop fertility problems, cancer or damage to their genes, all of which Merck admits in its product insert that it has not studied at all? We just don't know enough to be mandating GARDASIL for anyone, much less vulnerable 11 to 12 year old girls entering puberty."
http://www.medicalnewstoday.com/articles/63586.php

http://www.britannica.com/eb/topic-96872/carrageenan
carrageenan, a seaweed derivative that inhibits the human papillomavirus (HPV), the virus that causes cervical cancer and genital warts. Christopher Buck and his colleagues at the National Cancer Institute in Bethesda, Maryland, discovered that carrageenan's molecular structure blocks the virus. No other microbicide inhibits HPV. Reading Level (Lexile): 1300;
#
Spermicide Flip Side.

http://evil****opia.blogspot.com/2007/05/gardasil-2.html

9. There is a product called carrageenan that may be effective at preventing HPV infection.

Some early research has shown that carrageenan, a thickening agent derived from algae, is a powerful HPV inhibitor.

In laboratory tests, carrageenan, a compound derived from red algae, prevented HPV infection by both genital wart and cancer-causing types. "We were floored by how much better it worked than anything else we have tested. It's effective at 100-fold lower concentration than the next best inhibitor we've found," said Dr. John Schiller, senior investigator at the National Cancer Institute.

Normally, HPV attacks cells by attaching to proteins on their surface and then chemically manipulating access to the cells. Carrageenan thwarts this process by attaching to HPV and preventing its entry into cells. [Medical News Today][CBS News]

Carrageenan has also been studied for its ability to prevent herpes and HIV transmission, but it was found to be much more powerful at inhibiting HPV transmission. Carrageenan is used in a variety of commercial products, including some sexual lubricants and lubricated condoms.
Clinical trials could determine whether carrageenan could be successfully and safely used as a topical microbicide to prevent the spread of HPV. Since carageenan is already used in a variety of food, cosmetics, and sex-related products, it seems possible that a product like this could be developed. If so, it would be a powerful and relatively inexpensive tool in the fight against HPV, which would be especially beneficial in lower income countries around the world where women have limited access to health care and cervical cancer is a significant problem.

Clayton Young, an obstetrician/gynecologist in Texas, objects to Merck's claim that Gardasil will prevent cervical cancer. "There is no proof Gardasil will stop cervical cancer," he said. "They haven't been studying it long enough to make that claim.".

http://www.medicalobserver.com.au/displaya...ID=105&sl=1

Her mother, Annie McCrindle, doubted the vaccine would work, having seen both her children contract rubella despite being vaccinated as infants.

“If the vaccine might not work, why would I put this substance into my kid’s body?” she says.

http://vaccinations.suite101.com/article.c...er_and_gardasil

Gardasil Safety

Long term safety and efficacy studies have not been done on Gardasil. The FDA approved the vaccine based on short term benefits (24 months after the first injection) in women aged 16-26 and a study showing an immune effect in girls aged 9-15. Though the 90-100% efficacy seen in the short term studies is impressive, there have been no studies about the safety of using the vaccine in young girls and no studies of the effect on pregnancies that may occur within 30 days of receiving the vaccine, though it is advised that women thought to be pregnant should not receive the vaccine. However, in the FDA approval it was noted that Merck has promised the FDA that those studies will be done “post-marketing”.




The Cervical Cancer Vaccine

The vaccine contains purified viral proteins, called L1. They are non-infectious, but have been shown to activate the immune system in an identical manner to HPV infection. The proteins are injected with an adjuvant, a substance that helps speed the actions of the protein within the vaccine. In the case of Gardasil the adjuvant is an aluminum salt, despite a 2001 research study which found that the HPV-16 L1 protein is sufficient for an immune response and does not need an adjuvant.

the vaccine contains purified viral proteins, called L1.

http://www.freepatentsonline.com/EP1243655.html

15. A pharmaceutical composition comprising a DNA sequence of any one of claims 1 to 8, an expression vector of any one of claims 9 to 11, the E6 or E7 fusion protein of claim 13 or the E6 or E7 fusion protein produced according to the method of claim 14 in a pharmaceutically acceptable carrier.

18. Use of an E6 or E7 fusion protein according to claim 13 or produced according to the method of claim 14 in an in vitro assay for the detection of specific antibodies or cytotoxic T lymphocytes in a sample obtained from a subject infected by HPV.

19. Use of a transgenic mouse line transformed with a DNA sequence according to any one of claims 1 to 8 or an expression vector of any one of claims 9 to 11 for testing vaccines against HPV in vitro.






However, unfortunately, the above strategies exhibit a variety of disadvantages which so far have hampered the development of a safe and efficient vaccine. As regards the use of synthetic antigenic peptides it has to be stressed that the identification of HPV specific, immunoreactive peptides is very complex. It requires large numbers and quantities of peptides for vaccines to be effective and of a broad spectrum. Moreover, synthetic peptides do not contain posttranslational modifications (e.g., glycosylation, sulfation, phosphorylation) normally found in native proteins and therefore are not efficient enough as vaccines. The BCG based vaccine delivery systems expressing the L1 late protein of HPV 6b or the E7 early protein of HPV 16 have been used as immunogens. However, the immune responses obtained with these systems was even less than those elicited by protein/adjuvant vaccines and, thus, this system is considered unlikely to be useful as a single component vaccine strategy. As regards DNA vaccines it has been observed that the expression of wild-type HPV genes is quite low, even if they are expressed from strong promoters, such as that of the cytomegalovirus (CMV). As regards the use of Virus-like particles (VLPs) it has to be mentioned that true VLPs are made of the L1 (capsid) protein of a specific HPV type. Therefore, they may be only useful as prophylactic rather than as therapeutic vaccines, if ever. Pseudotyped VLPs containing, for instance, epitopes of HPV-16 E7 have also been described and may be useful as prophylactic and therapeutic vaccines. However, an important limitation is that VLPs are produced in insect cells or in yeast. So far, no suitable production systems in mammalian cells have been established. Therefore critical epitopes depending on posttranslational modifications which take place in human cells are lost in these systems.

Therefore, it is the object of the present invention to provide a safe and effective vaccine, preferably a genetic vaccine, for the treatment or prevention of an HPV infection or a neoplasm associated to HPV.

According to the invention this is achieved by the subject matters defined in the.claims. The present invention provides DNA sequences for inducing immune response to the E6 and/or E7 proteins of oncogenic HPV in a host animal, preferably by administering vectors containing said DNA sequences, e.g. plasmid vectors, herpes simplex virus type 1 amplicon or recombinant Semliki forest virus vectors. Said DNA sequences encode the HPV proteins as fusion proteins that are immunogenic but are not capable of inducing cell transformation. The DNA sequences of the invention are characterized bay the following features:

1. (a) The DNA sequences of the HPV E6/E7 genes have been modified to make their codon usage closer to that of human genes, i.e., at least 20% of the original codons are exchanged by codons which lead to an enhanced translation in a mammalian cell, ( the genes have been modified by mutation to make them non-functional, thereby' disabling their oncogenic capability (deletions are, preferably, point mutations, because these lead to loss of potentially essential epitopes), © the HPV genes have been fused to highly immunogenic proteins to enhance their immunogenicity in the host (these fusions are not expected to result in masking of HPV protein epitopes, since the fragments fused are of sufficient length as to avoid this problem), and, preferably, expression of the HPV genes is provided by recombinant, replication-deficient HSV, SFV or high copy plasmid vectors or combinations of these.


The expression "orignial codons" refers to the codons found in the corresponding wildtype version of the HPV.

The expression "enhanced translation in a mammalian cell" refers to the genes resulting from introduction of silent mutations in the HPV sequences, as described in the present invention, which create open reading frames consisting entirely of preferred human codons, and thus lead to enhanced expression of the proteins they encode in mammalian cells.

http://www.jneurosci.org/cgi/content/full/20/15/5696


Clinical Mutations in the L1 Neural Cell Adhesion Molecule Affect Cell-Surface Expression

Mutations in the L1 neural cell adhesion molecule, a transmembrane glycoprotein, cause a spectrum of congenital neurological syndromes, ranging from hydrocephalus to mental r******ation. Many of these mutations are single amino acid changes that are distributed throughout the various domains of the protein. Defective herpes simplex virus vectors were used to express L1 protein with the clinical missense mutations R184Q and D598N in the Ig2 and Ig6 extracellular domains, respectively, and S1194L in the cytoplasmic domain. All three mutant proteins were expressed at similar levels in infected cells. Neurite outgrowth of cerebellar granule cells was stimulated on astrocytes expressing wild-type or S1194L L1, whereas those expressing R184Q and D598N L1 failed to increase neurite length. Live cell immunofluorescent staining of L1 demonstrated that most defective vector-infected cells did not express R184Q or D598N L1 on their cell surface. This greatly diminished cell-surface expression occurred in astrocytes, neurons, and non-neural cells. In contrast to wild-type or S1194L L1, the R184Q and D598N L1 proteins had altered apparent molecular weights and remained completely endoglycosidase H (endoH)-sensitive, suggesting incomplete post-translational processing. We propose that some missense mutations in human L1 impede correct protein trafficking, with functional consequences independent of protein activity. This provides a rationale for how expressed, full-length proteins with single amino acid changes could cause clinical phenotypes similar in severity to knock-out mutants.

Hello. I came across your website while researching the side effects of Gardasil.

My 11 year old daughter is having health problems from getting the series of shots.

We have been going thru this since August:

*Flu like symptoms
*low grade fever
*fatigue
*abdominal pain
*kidney issues
*headaches
*thyroid problems
*weight gain
*no period in over a year
*rash on her face, neck and chest
*a seizure

She was a healthy and happy before getting the shots. Now she is too tired to do anything.


Shes had all kinds of blood work, EKG, EEG and an MRI. She has been
seen by 2 Pediatricians, a Nephrologist, Endocrinologist and has an
appointment with a Neurologist at the end of this month.


Every test is coming back normal. The doctors dont know what is the matter with her.

There are lots of others that are experiencing the same side effects. I wish that I had known this before she got the shots.

My younger daughter sure wont get them!!!!